Microfluidic Organ-on-Chip Drug Testing Market
The microfluidic organ-on-chip drug testing market is segmented by Organ Model (Liver-on-chip, Kidney-on-chip, Lung-on-chip, Gut/intestine-on-chip, Heart-on-chip, Brain/CNS-on-chip, Tumor-on-chip, Multi-organ/body-on-chip), Application (Preclinical toxicology and safety screening, ADME / DMPK testing, Efficacy and mechanism studies, Disease modelling for candidate selection, Biologics and advanced modality testing, Personalized / patient-derived response testing), End User (Pharmaceutical and biotechnology companies, CROs / contract testing labs, Academic and translational research institutes, Regulatory and public-sector research programs), Platform Format (Single-organ microfluidic chips, Multi-organ interconnected systems, High-throughput plate-compatible platforms, AI-integrated / sensor-enabled systems), Workflow Model (Instrument and consumables sales, Contract research services, Collaborative validation programs, Software / analytics / imaging add-ons), and Region. Forecast for 2026 to 2036.
